Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tivozanib, a highly potent and selective inhibitor of VEGF receptor tyrosine kinases, for the treatment of metastatic renal cell carcinoma.

Future oncology (London, England) - 1 Oct 2020

Jacob Allen, Shook Jaret, Hutson Thomas E

Abstract excerpt

The VHL mutation-HIF upregulation-VEGF transcription sequence is the principal pathway in the development of renal cell carcinoma. Tyrosine kinase inhibitors target the VEGF receptors to inhibit further growth of renal cell carcinoma tumors. Tivozanib, originally named AV-951 and KRN-951, is a novel, orally bioavailable VEGF tyrosine kinase inhibitor that is selective for VEGF receptors 1, 2 and 3. Further, only...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Renal Cell
Share to Clinical Trials, Phase I as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials, Phase II as Topic

Share to Clinical Trials, Phase III as Topic

Share to Phenylurea Compounds

Share to Quinolines

Share to Randomized Controlled Trials as Topic

Share to Receptors, Vascular Endothelial Growth Factor

Source

Identifiers

PMID: 32692256
DOI: 10.2217/fon-2020-0443

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tivozanib, a highly potent and selective inhibitor of VEGF receptor tyrosine kinases, for the treatment of metastatic renal cell carcinoma.PMID 32692256Read ↗

Hypoxia-Inducible Factor in Renal Cell Carcinoma: From Molecular Insights to Targeted TherapiesSemantic proximity Read ↗

Development of drugs targeting hypoxia-inducible factor against tumor cells with VHL mutation: Story of 127 years.Semantic proximity Read ↗

The implementation of lenvatinib/everolimus or lenvatinib/pembrolizumab combinations in the treatment of metastatic renal cell carcinoma.Semantic proximity Read ↗

MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinomaSemantic proximity Read ↗

Molecular basis for the treatment of renal cell carcinoma.Semantic proximity Read ↗

A novel vascular endothelial growth factor-trap KP-VR2 with enhanced ligand blockingSemantic proximity Read ↗

Real-world efficacy and safety of belzutifan in patients with metastatic renal cell carcinoma: a multicenter retrospective study in JapanSemantic proximity Read ↗

Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.Semantic proximity Read ↗

Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC.Semantic proximity Read ↗

Differential Effects of HIF2α Antagonist and HIF2α Silencing in Renal Cancer and Sensitivity to Repurposed DrugsSemantic proximity Read ↗

Belzutifan, HIF-2α Inhibitor, and Clear Cell Renal Cell Carcinoma With Somatic Von-Hippel-Lindau Loss-of-Function Mutation.Semantic proximity Read ↗

Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor HypoxiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.